From Passive To Predictive: The New Era Of Clinical Cold Chain Management

By Michael Tong and Harshita Jain, FTI Consulting

In clinical development, temperature-controlled logistics has always been high-stakes. Today, however, the landscape is intensifying. As breakthrough temperature-sensitive drugs accelerate and trials expand across increasingly fragmented global networks, the cold chain is shedding its skin. It is no longer a passive support function – it has become a continuously managed, interconnected function.

While a minor deviation can still jeopardize years of research, today’s digital infrastructure allows us to anticipate failures before they occur. For biotechnology companies, the mandate is clear: innovate the cold chain or risk the trial.

This pressure is driving a fundamental shift in cold chain management, one defined by three pillars: predictive control, resilient risk planning, and radical cross-functional transparency.

1. Predictive Control: Moving To Anticipatory Control Systems

The industry is moving away from post-mortem data reviews. Reviewing temperature logs after a shipment arrives is no longer sufficient; the goal now is to flag risks in real time.

• Data as an Operational Tool: Regulators (FDA and EMA) now expect continuous oversight rather than intermittent check-ins. ^{1, 2} Passive monitors, such as simple chemical stickers, are being replaced by active digital sensors. This isn’t just for compliance – it’s for the data integrity of the trial itself.
• The Chain of Identity: In cell and gene therapy (CGT), tracking is not only about heat; it's about patient safety. Robust tracking ensures the right treatment reaches the right patient, protecting both the subject and the clinical findings.³
• Intelligent Monitoring Platforms: Leading logistics providers are championing centralized digital dashboards.⁴ By integrating live geolocation with atmospheric data, teams can pivot during transit. Previously, global dead zones made this impossible, but near-global cloud coverage now allows for effortless processing of massive data streams, even during long-haul flights.

2. Resilient Risk Planning: Resilience Through Scenario-Based Planning

Identifying a risk is only half the battle; the speed of the response determines whether a shipment is salvaged or scrapped.

• Beyond Documentation: Industry standards like USP <1079&GT make it clear: biologics can degrade in minutes. ^{5, 6} To combat this, companies are moving toward "playbook" logistics.
• The Power of the Playbook: What happens if a shipment is flagged at a border? What if a logistics handoff is delayed by a strike? Scenario-based planning allows teams to intervene with precision.
• Building Redundancy: True resilience requires physical backups. This includes nested packaging, backup refrigerants, and diversified courier networks to ensure that if Plan A fails, the medicine remains stable.⁷

3. Radical Cross-Functional Transparency: Deeply Collaborative Coordination

The cold chain is too complex for any single department to own. It requires a "symphony" approach between sponsors, CROs, couriers and clinical sites.

Poor coordination — especially during international handoffs — remains the leading cause of documentation gaps and excursion risks.⁸

To mitigate this, forward-thinking companies are investing in organizational readiness:

1. Cross-Functional Rehearsals: Move beyond SOPs to live-fire logistics drills.
2. Defined Escalation Pathways: Ensure that when a sensor pings an alert, the right person is notified and authorized to act immediately.⁹
3. Unified Training: Ensure that every stakeholder, from the warehouse floor to the clinical site, understands the specific stability profile of the drug.

The Strategic Differentiator

Clinical development is the proving ground where scientific concepts become operational realities. As we look ahead, a scalable cold-chain function is no longer a logistics cost – it is a strategic differentiator.

By moving toward a model that is predictive, resilient, and collaborative, biotech companies do more than just protect their product; they protect their patients and the future of their science.

This is especially critical for companies approaching commercialization. As we explored in our recent piece, From Lab to Launch: Navigating the Transition to Commercial Readiness, the transition from clinical to commercial scale requires tight alignment between strategy, operations, and finance. Cold chain is no exception. Organizations that treat cold chain readiness as part of their broader commercialization planning, rather than a downstream logistics problem, are better positioned to launch on time and at scale.

As modalities diversify and trial designs globalize, the cold chain must evolve into a predictive, resilience-driven function that:

• uses real-time data to anticipate disruptions
• applies rigorous scenario-based risk-management frameworks
• coordinates seamlessly across global teams
• supports the transition from clinical to commercial supply.

References:

1. "CGMP for Phase 1 Investigational Drugs: Guidance for Industry." FDA.gov. U.S. Food and Drug Administration, July 2008. https://www.fda.gov/media/70975/download.
2. "Guidelines on Good Distribution Practice of Medicinal Products for Human Use." EUR-Lex. European Union, November 5, 2013. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=oj:JOC_2013_343_R_0001_01.
3. "Frequently Asked Questions: Developing Potential Cellular and Gene Therapy Products." FDA.gov. U.S. Food and Drug Administration, November 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-developing-potential-cellular-and-gene-therapy-products.
4. "Key Logistics Trends in Life Sciences 2020+: How to Prepare for Future Growth." DHL.com. Deutsche Post DHL Group, 2020. https://www.dhl.com/gb-en/home/insights-and-innovation/thought-leadership/trend-reports/key-logistics-trends-in-life-sciences-2020.html.
5. "General Chapters: <1079&GT Good Storage and Shipping Practices." USP-NF. United States Pharmacopeia, n.d. http://ftp.uspbpep.com/v29240/usp29nf24s0_c1079.html.
6. Peláez, Sarah S., Hanns-Christian Mahler, Jörg Huwyler, and Andrea Allmendinger. "Directional Freezing and Thawing of Biologics in Drug Substance Bottles." European Journal of Pharmaceutics and Biopharmaceutics 203 (2024): 114427. https://doi.org/10.1016/j.ejpb.2024.114427.
7. "Cold Chain Solutions: Shipping, Packaging, and Storage." UPS.com. UPS Healthcare, n.d. https://www.ups.com/us/en/healthcare/solutions/coldchain.
8. Desai, K.G., J.D. Colandene, and M. Adams. "Comprehensive Temperature Excursion Management Program for the Commercial Distribution of Biopharmaceutical Drug Products." Journal of Pharmaceutical Sciences 109, no. 7 (July 2020): 2131-2144. https://pubmed.ncbi.nlm.nih.gov/32315663/.
9. "High-Fidelity Data and Real-Time Logistics Monitoring: Key in Preventing Temperature Excursions." WorldCourier.com. Cencora, April 14, 2024. https://www.worldcourier.com/insights/high-fidelity-data-and-rtlm-key-in-preventing-temperature-excursions.

Note: The views expressed herein are those of the author(s) and not necessarily the views of FTI Consulting, Inc., its management, its subsidiaries, its affiliates, or its other professionals. FTI Consulting, Inc., including its subsidiaries and affiliates, is a consulting firm and is not a certified public accounting firm or a law firm.

About The Authors:

Michael Tong: Michael Tong is a leader within the life sciences industry with more than 15 years of consulting and functional experience. He is responsible for the delivery of services and solutions focused on assisting life sciences clients with solving their most complex problems and achieving their strategic and operational objectives. His experience spans multiple industries with a focus on life sciences — including consumer, pharmaceutical, medical devices, and personalized medicine — and supply chain functions such as manufacturing, logistics, distribution, global trade, control tower, sourcing and procurement and end-to-end commercialization.

Harshita Jain is a life sciences consultant and helps biotechnology clients address complex challenges and advance strategic and operational objectives. Her background is in process optimization and enhancement, with a focus on supply chain and operations, and she has experience across the industry, including with biologics, pharmaceuticals, and medical device companies. She has done extensive work with temperature-controlled logistics and shipping validation in clinical and commercial settings and is focused on achieving patient-oriented outcomes alongside organization efficiency and risk mitigation.